Cargando…

Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease

PURPOSE: Metabolic associated fatty liver disease is a novel concept defined as fatty liver associated with metabolic disorders. We investigated the effect of metabolic associated fatty liver disease on hepatocellular carcinoma patient mortality. PATIENTS AND METHODS: A total of 624 patients with he...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Yajing, Yang, Tao, Wei, Shuhang, Liu, Zongxin, Liu, Chenxi, Shen, Zijian, Yang, Yinuo, Feng, Yuemin, Yao, Ping, Zhu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404410/
https://www.ncbi.nlm.nih.gov/pubmed/37551338
http://dx.doi.org/10.2147/DMSO.S416280
_version_ 1785085292006342656
author You, Yajing
Yang, Tao
Wei, Shuhang
Liu, Zongxin
Liu, Chenxi
Shen, Zijian
Yang, Yinuo
Feng, Yuemin
Yao, Ping
Zhu, Qiang
author_facet You, Yajing
Yang, Tao
Wei, Shuhang
Liu, Zongxin
Liu, Chenxi
Shen, Zijian
Yang, Yinuo
Feng, Yuemin
Yao, Ping
Zhu, Qiang
author_sort You, Yajing
collection PubMed
description PURPOSE: Metabolic associated fatty liver disease is a novel concept defined as fatty liver associated with metabolic disorders. We investigated the effect of metabolic associated fatty liver disease on hepatocellular carcinoma patient mortality. PATIENTS AND METHODS: A total of 624 patients with hepatocellular carcinoma between 2012 and 2020 were enrolled in this retrospective study. Hepatic steatosis was diagnosed using computed tomography or magnetic resonance imaging. Metabolic associated fatty liver disease was defined based on the proposed criteria in 2020. Propensity score matching was performed for patients with metabolic associated fatty liver disease and those without the condition. A Cox proportional hazards regression model was used to evaluate the association between metabolic associated fatty liver disease and hepatocellular carcinoma patient outcomes. RESULTS: Patients with hepatocellular carcinoma and metabolic associated fatty liver disease tended to achieve better outcomes than did those without metabolic associated fatty liver disease after matching (p<0.001). Metabolic associated fatty liver disease was significantly associated with better prognosis in patients with concurrent hepatitis B infection (p<0.001). Moreover, high levels of hepatitis B viral DNA in serum samples was associated with a significantly increased risk of death in patients without non-metabolic associated fatty liver disease (p=0.045). Additionally, the association between metabolic associated fatty liver disease and survival in hepatitis B virus-related hepatocellular carcinoma was similar in all subgroups based on metabolic traits. CONCLUSION: Metabolic associated fatty liver disease increases the survival rate of patients with hepatocellular carcinoma and hepatitis B virus infection. The potential interaction of steatosis and virus replication should be considered for future research and clinical treatment strategies.
format Online
Article
Text
id pubmed-10404410
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104044102023-08-07 Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease You, Yajing Yang, Tao Wei, Shuhang Liu, Zongxin Liu, Chenxi Shen, Zijian Yang, Yinuo Feng, Yuemin Yao, Ping Zhu, Qiang Diabetes Metab Syndr Obes Original Research PURPOSE: Metabolic associated fatty liver disease is a novel concept defined as fatty liver associated with metabolic disorders. We investigated the effect of metabolic associated fatty liver disease on hepatocellular carcinoma patient mortality. PATIENTS AND METHODS: A total of 624 patients with hepatocellular carcinoma between 2012 and 2020 were enrolled in this retrospective study. Hepatic steatosis was diagnosed using computed tomography or magnetic resonance imaging. Metabolic associated fatty liver disease was defined based on the proposed criteria in 2020. Propensity score matching was performed for patients with metabolic associated fatty liver disease and those without the condition. A Cox proportional hazards regression model was used to evaluate the association between metabolic associated fatty liver disease and hepatocellular carcinoma patient outcomes. RESULTS: Patients with hepatocellular carcinoma and metabolic associated fatty liver disease tended to achieve better outcomes than did those without metabolic associated fatty liver disease after matching (p<0.001). Metabolic associated fatty liver disease was significantly associated with better prognosis in patients with concurrent hepatitis B infection (p<0.001). Moreover, high levels of hepatitis B viral DNA in serum samples was associated with a significantly increased risk of death in patients without non-metabolic associated fatty liver disease (p=0.045). Additionally, the association between metabolic associated fatty liver disease and survival in hepatitis B virus-related hepatocellular carcinoma was similar in all subgroups based on metabolic traits. CONCLUSION: Metabolic associated fatty liver disease increases the survival rate of patients with hepatocellular carcinoma and hepatitis B virus infection. The potential interaction of steatosis and virus replication should be considered for future research and clinical treatment strategies. Dove 2023-08-02 /pmc/articles/PMC10404410/ /pubmed/37551338 http://dx.doi.org/10.2147/DMSO.S416280 Text en © 2023 You et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
You, Yajing
Yang, Tao
Wei, Shuhang
Liu, Zongxin
Liu, Chenxi
Shen, Zijian
Yang, Yinuo
Feng, Yuemin
Yao, Ping
Zhu, Qiang
Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease
title Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease
title_full Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease
title_fullStr Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease
title_full_unstemmed Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease
title_short Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease
title_sort survival of patients with hepatitis b-related hepatocellular carcinoma with concomitant metabolic associated fatty liver disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404410/
https://www.ncbi.nlm.nih.gov/pubmed/37551338
http://dx.doi.org/10.2147/DMSO.S416280
work_keys_str_mv AT youyajing survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease
AT yangtao survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease
AT weishuhang survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease
AT liuzongxin survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease
AT liuchenxi survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease
AT shenzijian survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease
AT yangyinuo survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease
AT fengyuemin survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease
AT yaoping survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease
AT zhuqiang survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease